Results from the melanoma cohort of the phase 1/2 MATINS show the potential of bexmarilimab monotherapy and combined with other immunotherapies across solid tumors and hematologic malignancies.
Clinical Trials
Nivolumab significantly prolongs recurrence-free survival in resected stage II melanoma
Nivolumab conferred a statistically significant and clinically meaningful improvement in recurrence-free survival vs. placebo among patients with completely resected stage IIB or IIC melanoma, according to the agent’s manufacturer.
Adjuvant Nivolumab Reduces Risk of Recurrence or Death by 58% in Select Stage IIB or IIC Melanoma
Adjuvant treatment with nivolumab (Opdivo) resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) over placebo in patients with completely resected stage IIB or IIC melanoma, meeting the primary end point of the phase 3 CheckMate-76K trial (NCT04099251).
Adjuvant Nivolumab Demonstrates Reduced Risk of Death or Recurrence Vs Placebo in Stage IIB/C Melanoma
Patients with completely resected stage IIB/C melanoma experienced significant and clinically meaningful improvements in recurrence-free survival following treatment with adjuvant nivolumab compared with placebo.